Prostate: 前列腺癌生化复发患者长期癌症控制结果相关研究

2018-03-29 AlexYang MedSci原创

转移性恶化(MP)的速度和前列腺癌致死率(PCSM)在经历过根治性前列腺癌切除(RP)的患者中的生化复发之后,是多样化的。最近,有研究人员描述了BCR患者的长期肿瘤治疗结果,并且在这些男性中,特别聚焦RP到BCR之间的时间,为进一步的治疗结果分析了相关的风险因子。研究人员回顾性的分析了5509名RP患者的数据。研究包括了1321名经历过BCR的患者,并且他们没有接受任何的新辅助疗法或者辅助治疗。研

转移性恶化(MP)的速度和前列腺癌致死率(PCSM)在经历过根治性前列腺癌切除(RP)的患者中的生化复发之后,是多样化的。最近,有研究人员描述了BCR患者的长期肿瘤治疗结果,并且在这些男性中,特别聚焦RP到BCR之间的时间,为进一步的治疗结果分析了相关的风险因子。

研究人员回顾性的分析了5509名RP患者的数据。研究包括了1321名经历过BCR的患者,并且他们没有接受任何的新辅助疗法或者辅助治疗。研究发现,平均的跟踪调查时间为121个月,并在177(13.4%)名中记录了MP,在126(9.5%)名中记录了PCSM和在264名(20%)中记录了总死亡率(OM)。那些具有MP的患者具有更糟糕的肿瘤特性,比如更高的格林森得分(GS)、快速的PSA倍增时间(DT)和更短的RP和BCR时间间隔。与那些RP-BCR时间间隔在12-35.9个月或者不小于36个月的患者中,无MP、无PCSM和总生存率在RP-BCR之间时间间隔小于12个月的患者中更差(P≤0.001)。除了更高的GS和快速的PSA-DT,RP-BCR时间在多变量回归分析中能够独立的预测MP、PCSM和OM。另外,相对于中等程度和最长的RP-BCR时间间隔,最短的时间间隔(小于12个月)具有上述3个端点最高的风险。

最后,研究人员指出,只有小比例的BCR患者能够发展成为MP 或者PCSM。除了更高GS和快速的PSA-DT,更短的RP-BCR时间间隔(小于12个月)在表型恶化进展到3个端点MP、PCSM和OM中具有重要的预示作用。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1800486, encodeId=93a21800486ff, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Oct 06 12:41:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364318, encodeId=e1181364318a5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384583, encodeId=42891384583a3, content=<a href='/topic/show?id=06e068891d4' target=_blank style='color:#2F92EE;'>#生化复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68891, encryptionId=06e068891d4, topicName=生化复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601991, encodeId=676616019912a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300944, encodeId=001b300944f4, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Mar 29 22:16:26 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300940, encodeId=f68e30094098, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Mar 29 22:14:52 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1800486, encodeId=93a21800486ff, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Oct 06 12:41:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364318, encodeId=e1181364318a5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384583, encodeId=42891384583a3, content=<a href='/topic/show?id=06e068891d4' target=_blank style='color:#2F92EE;'>#生化复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68891, encryptionId=06e068891d4, topicName=生化复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601991, encodeId=676616019912a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300944, encodeId=001b300944f4, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Mar 29 22:16:26 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300940, encodeId=f68e30094098, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Mar 29 22:14:52 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-03-31 lsndxfj
  3. [GetPortalCommentsPageByObjectIdResponse(id=1800486, encodeId=93a21800486ff, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Oct 06 12:41:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364318, encodeId=e1181364318a5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384583, encodeId=42891384583a3, content=<a href='/topic/show?id=06e068891d4' target=_blank style='color:#2F92EE;'>#生化复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68891, encryptionId=06e068891d4, topicName=生化复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601991, encodeId=676616019912a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300944, encodeId=001b300944f4, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Mar 29 22:16:26 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300940, encodeId=f68e30094098, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Mar 29 22:14:52 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1800486, encodeId=93a21800486ff, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Oct 06 12:41:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364318, encodeId=e1181364318a5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384583, encodeId=42891384583a3, content=<a href='/topic/show?id=06e068891d4' target=_blank style='color:#2F92EE;'>#生化复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68891, encryptionId=06e068891d4, topicName=生化复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601991, encodeId=676616019912a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300944, encodeId=001b300944f4, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Mar 29 22:16:26 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300940, encodeId=f68e30094098, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Mar 29 22:14:52 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-03-31 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1800486, encodeId=93a21800486ff, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Oct 06 12:41:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364318, encodeId=e1181364318a5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384583, encodeId=42891384583a3, content=<a href='/topic/show?id=06e068891d4' target=_blank style='color:#2F92EE;'>#生化复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68891, encryptionId=06e068891d4, topicName=生化复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601991, encodeId=676616019912a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300944, encodeId=001b300944f4, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Mar 29 22:16:26 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300940, encodeId=f68e30094098, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Mar 29 22:14:52 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-03-29 天地飞扬

    了解一下.谢谢分享!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1800486, encodeId=93a21800486ff, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Oct 06 12:41:00 CST 2018, time=2018-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364318, encodeId=e1181364318a5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384583, encodeId=42891384583a3, content=<a href='/topic/show?id=06e068891d4' target=_blank style='color:#2F92EE;'>#生化复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68891, encryptionId=06e068891d4, topicName=生化复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601991, encodeId=676616019912a, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Mar 31 12:41:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300944, encodeId=001b300944f4, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Mar 29 22:16:26 CST 2018, time=2018-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=300940, encodeId=f68e30094098, content=不错的文章值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Thu Mar 29 22:14:52 CST 2018, time=2018-03-29, status=1, ipAttribution=)]
    2018-03-29 1e1b8538m79(暂无匿称)

    不错的文章值得拥有

    0

相关资讯

EAU18∣魏强教授团队:区域淋巴结及远处转移性前列腺癌的局部治疗研究进展

前列腺癌是威胁男性健康的常见肿瘤之一,全世界发生率位列男性肿瘤的第2位。初诊转移性前列腺癌患者5年生存率仅为28%。内分泌治疗及化疗是转移性前列腺癌的标准治疗方案,虽然能提高转移性前列腺癌患者的短期生存率,但对患者的远期生存率影响不大,且并发症较多。

Sci Rep:PSMA的表达是前列腺癌诊断潜在的有利因子

前列腺癌(PCa)病人是根据诊断时的临床阶段和PSA水平以及在前列腺活检时的格林森得分(GS)基础上进行风险分层的。然而,这些参数在区分高风险和低风险疾病中并不是完全的准确,从而促进了一个可以信赖的标记来确定侵入性能力的需要。前列腺特异性膜抗原(PSMA)也许能够满足这种需要。最近,有研究人员分析了79个前列腺活检案例和28个前列腺切除案例来评估是否PSMA表达与GS有关。研究发现,PSMA表达与

Brit J Cancer:芬兰人前列腺癌随机筛选研究中空腹血糖、血糖控制与前列腺癌风险关系研究

糖尿病男性具有更低的前列腺癌(PCa)总风险,但是高血糖征在其中的角色情况不清楚。在研究中,研究人员评估了具有糖尿病空腹血糖水平男性的PCa风险。研究人员将参与者与实验室数据相联系,目的是为了追溯自从1978年的血糖测量信息,可利用的数据涉及到17860名男性。根据年平均水平,这些男性被归类为正常血糖水平、糖尿病前期和糖尿病。平均跟踪调查的时间为14.7年。研究人员还利用调整后的多变量Cox回归计

Nat Commun:前列腺癌整体蛋白组学分析揭示了疾病恶化过程中基因组和转录组的变异

为了理解前列腺癌中基因和转录变异在功能上影响的结果,就需要对在疾病形成和恶化期间蛋白组的变化情况进行阐释。最近,有研究人员对良性前列腺增生(BPH)、未处理的初级前列腺癌(PC)和去势难治性前列腺癌(CRPC)临床组织样本进行了高通量的质谱分析。研究发现,每一个样本群体均表现出了不同的蛋白谱。通过综合的分析,研究人员展示了尤其在CRPC中,基因拷贝数、DNA甲基化和RNA表达水平不能可信的预测蛋白

Prostate Cancer P D: 免疫检查点阻断结合冷冻消融术在前列腺癌中治疗的分析

前列腺癌在男性中仍旧是癌症引起死亡的第二大主导因素。免疫检查点阻断抗体治疗彻底改变了多种实体肿瘤的治疗方式,但是在前列腺癌中的治疗结果仍旧不清楚。之间的研究表明了局部治疗,尤其是冷冻消融术治疗也许会增加肿瘤的免疫原性。最近,有研究人员调查了肿瘤冷冻消融术语检查点阻断抗体之间的潜在的协同作用。研究发现,利用抗CTLA-4抗体和冷冻消融术治疗,能够显著的推迟远距离肿瘤的生长,长达14.8天(p=0.0

Sci Rep:肌氨酸作为前列腺癌的犬类嗅觉检测靶标分子的鉴定

狗可以通过对特异性分子进行鉴别从而来检测恶性肿瘤的假说已经存在了将近30年。到目前为止,有一些报道描述了对不同类型癌症的成功的检测。然而,考虑到能够被狗嗅觉器官检测到的特异性分子,该方面的数据仍旧还有很大的欠缺。最近,有研究人员进行了相关研究,即研究人员人工准备了且已经详细鉴定过的富含肌氨酸的尿液样本,肌氨酸是广泛报道的前列腺癌(PCa)尿液生物标记。为了研究目的,研究人员使用了一只德国牧羊犬来对